95 related articles for article (PubMed ID: 23155226)
1. Biomarkers of pituitary neoplasms.
Sav A; Rotondo F; Syro LV; Scheithauer BW; Kovacs K
Anticancer Res; 2012 Nov; 32(11):4639-54. PubMed ID: 23155226
[TBL] [Abstract][Full Text] [Related]
2. Biomarkers of pituitary neoplasms: a review (Part II).
Salehi F; Agur A; Scheithauer BW; Kovacs K; Lloyd RV; Cusimano M
Neurosurgery; 2010 Dec; 67(6):1790-8; discussion 1798. PubMed ID: 21107210
[TBL] [Abstract][Full Text] [Related]
3. Differential expression of galectin-3 in pituitary tumors.
Riss D; Jin L; Qian X; Bayliss J; Scheithauer BW; Young WF; Vidal S; Kovacs K; Raz A; Lloyd RV
Cancer Res; 2003 May; 63(9):2251-5. PubMed ID: 12727847
[TBL] [Abstract][Full Text] [Related]
4. Biomarkers of aggressive pituitary adenomas.
Mete O; Ezzat S; Asa SL
J Mol Endocrinol; 2012 Oct; 49(2):R69-78. PubMed ID: 22822048
[TBL] [Abstract][Full Text] [Related]
5. Identification and consequences of galectin-3 expression in pituitary tumors.
Righi A; Jin L; Zhang S; Stilling G; Scheithauer BW; Kovacs K; Lloyd RV
Mol Cell Endocrinol; 2010 Sep; 326(1-2):8-14. PubMed ID: 20451577
[TBL] [Abstract][Full Text] [Related]
6. Proliferation markers of human pituitary tumors: contribution of a genome-wide transcriptome approach.
Wierinckx A; Raverot G; Nazaret N; Jouanneau E; Auger C; Lachuer J; Trouillas J
Mol Cell Endocrinol; 2010 Sep; 326(1-2):30-9. PubMed ID: 20211685
[TBL] [Abstract][Full Text] [Related]
7. A diagnostic marker set for invasion, proliferation, and aggressiveness of prolactin pituitary tumors.
Wierinckx A; Auger C; Devauchelle P; Reynaud A; Chevallier P; Jan M; Perrin G; Fèvre-Montange M; Rey C; Figarella-Branger D; Raverot G; Belin MF; Lachuer J; Trouillas J
Endocr Relat Cancer; 2007 Sep; 14(3):887-900. PubMed ID: 17914117
[TBL] [Abstract][Full Text] [Related]
8. Angiogenesis and pituitary tumors.
Cohen AB; Lessell S
Semin Ophthalmol; 2009; 24(3):185-9. PubMed ID: 19437356
[TBL] [Abstract][Full Text] [Related]
9. p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions.
Thapar K; Scheithauer BW; Kovacs K; Pernicone PJ; Laws ER
Neurosurgery; 1996 Apr; 38(4):765-70; discussion 770-1. PubMed ID: 8692397
[TBL] [Abstract][Full Text] [Related]
10. Pathogenesis of pituitary tumors.
Yu R; Melmed S
Prog Brain Res; 2010; 182():207-27. PubMed ID: 20541667
[TBL] [Abstract][Full Text] [Related]
11. Predictive markers of pituitary adenoma behavior.
Kontogeorgos G
Neuroendocrinology; 2006; 83(3-4):179-88. PubMed ID: 17047381
[TBL] [Abstract][Full Text] [Related]
12. Angiogenesis in pituitary adenomas.
Yamada S; Takada K
Microsc Res Tech; 2003 Feb; 60(2):236-43. PubMed ID: 12539178
[TBL] [Abstract][Full Text] [Related]
13. Coexpression of survivin and PCNA in pituitary tumors and normal pituitary.
Wasko R; Waligorska-Stachura J; Jankowska A; Warchol JB; Liebert W; Sowinski J
Neuro Endocrinol Lett; 2009; 30(4):477-81. PubMed ID: 20010504
[TBL] [Abstract][Full Text] [Related]
14. Indices of apoptosis and proliferation as potential prognostic markers in non-functioning pituitary adenomas.
Ibrahim AE; Pickering RM; Gawne-Cain ML; King S; Lees PD; Ellison DW
Clin Neuropathol; 2004; 23(1):8-15. PubMed ID: 14986928
[TBL] [Abstract][Full Text] [Related]
15. Oncogenesis and mutagenesis of pituitary tumors.
Sonabend AM; Musleh W; Lesniak MS
Expert Rev Anticancer Ther; 2006 Sep; 6 Suppl 9():S3-14. PubMed ID: 17004855
[TBL] [Abstract][Full Text] [Related]
16. Angiogenesis in normal and neoplastic pituitary tissues.
Lloyd RV; Vidal S; Horvath E; Kovacs K; Scheithauer B
Microsc Res Tech; 2003 Feb; 60(2):244-50. PubMed ID: 12539179
[TBL] [Abstract][Full Text] [Related]
17. Clinical tumor growth and comparison with proliferation markers in non-functioning (inactive) pituitary adenomas.
Saeger W; Lüdecke B; Lüdecke DK
Exp Clin Endocrinol Diabetes; 2008 Feb; 116(2):80-5. PubMed ID: 18072009
[TBL] [Abstract][Full Text] [Related]
18. Pathobiology of pituitary adenomas and carcinomas.
Scheithauer BW; Gaffey TA; Lloyd RV; Sebo TJ; Kovacs KT; Horvath E; Yapicier O; Young WF; Meyer FB; Kuroki T; Riehle DL; Laws ER
Neurosurgery; 2006 Aug; 59(2):341-53; discussion 341-53. PubMed ID: 16883174
[TBL] [Abstract][Full Text] [Related]
19. Expression of cyclooxygenase-2 in advanced stage ovarian serous carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, and survival.
Ali-Fehmi R; Morris RT; Bandyopadhyay S; Che M; Schimp V; Malone JM; Munkarah AR
Am J Obstet Gynecol; 2005 Mar; 192(3):819-25. PubMed ID: 15746677
[TBL] [Abstract][Full Text] [Related]
20. Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis.
Heaney AP; Horwitz GA; Wang Z; Singson R; Melmed S
Nat Med; 1999 Nov; 5(11):1317-21. PubMed ID: 10546001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
